Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid		6.00%
Research and development		$ 1,618,889	$ 2,611,591	$ 2,885,952	$ 4,605,692
Agreement expiration date				May 31, 2027
Description on termination of agreement				The Company may terminate the Restated Agreement at any time upon 90 days’ written notice and may terminate any development plan under the Restated Agreement upon 30 days’ prior written notice. Illumina may terminate the Restated Agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control, subject to a transition period of up to 12 months for then-ongoing development plans. Either party may terminate the Restated Agreement upon the other party’s material breach of the Restated Agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.
Service revenue for research and development services		1,353,579	$ 1,318,689	$ 2,183,604	$ 1,583,731
Merck KGaA Agreement
Other Agreements [Line Items]
Service revenue for research and development services		25,000		25,000
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	$ 600,000	600,000		600,000
Additional contractual milestons payment						$ 0
Research and development		50,000		50,000
Agreement termination notice period	90 days
Development plan agreement termination notice period	30 days
Number of days material breach remains uncured	30 days
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	$ 400,000	$ 400,000		$ 400,000